MedPath

Bepotastine Besilate

These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION.BEPOTASTINE BESILATE OPHTHALMIC SOLUTION, 1.5%, for topical ophthalmic useInitial U.S. Approval: 2009

Approved
Approval ID

995f4fe0-d861-4137-8090-a8ffc71c46f4

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 31, 2020

Manufacturers
FDA

Bausch & Lomb Incorporated

DUNS: 196603781

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

bepotastine besilate

PRODUCT DETAILS

NDC Product Code24208-630
Application NumberNDA022288
Marketing CategoryC73605
Route of AdministrationOPHTHALMIC
Effective DateDecember 31, 2020
Generic Namebepotastine besilate

INGREDIENTS (6)

BEPOTASTINE BESILATEActive
Quantity: 15 mg in 1 mL
Code: 6W18MO1QR3
Classification: ACTIB
BENZALKONIUM CHLORIDEInactive
Quantity: 0.05 mg in 1 mL
Code: F5UM2KM3W7
Classification: IACT
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATEInactive
Code: 5QWK665956
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Bepotastine Besilate - FDA Drug Approval Details